Login to Your Account

Death in Cellectis CAR T trial leads to clinical hold

By Michael Fitzhugh
Staff Writer

Tuesday, September 5, 2017

The death of a 78-year-old man with a rare blood cancer in an early trial of Cellectis SA's gene-edited CAR T therapy, UCART-123, triggered an FDA clinical hold on the study and a second test of the experimental treatment.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription